Efferocytosis: A new therapeutic target for stroke.
10.1097/CM9.0000000000003363
- Author:
Li GAO
1
;
Anatol MANAENKO
2
;
Feng ZENG
3
;
Jingchen LI
4
;
Lele LIU
4
;
Ruichuan XIE
4
;
Xiaohua ZHANG
1
;
John H ZHANG
5
;
Qiyong MEI
3
;
Jiping TANG
5
;
Qin HU
1
Author Information
1. Department of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
2. Clinical Neuroanatomy, Department of Neurology, School of Medicine, Ulm University, Ulm 89081, Germany.
3. Department of Neurosurgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
4. Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
5. Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, USA.
- Publication Type:Review
- MeSH:
Humans;
Stroke;
Phagocytosis/physiology*;
Inflammation;
Apoptosis/physiology*;
Animals;
Phagocytes/physiology*;
Brain/metabolism*;
Efferocytosis
- From:
Chinese Medical Journal
2024;137(23):2843-2850
- CountryChina
- Language:English
-
Abstract:
Efferocytosis refers to the process that phagocytes recognize and remove the apoptotic cells, which is essential for maintaining tissue homeostasis both in physiological and pathological conditions. Numerous studies have demonstrated that efferocytosis can prevent secondary necrosis and proinflammatory factor release, leading to the resolution of inflammation and tissue immunological tolerance in numerous diseases such as stroke. Stroke is a leading cause of death and morbidity for adults worldwide. Persistent inflammation triggered by the dead cells or cell debris is a major contributor to post-stroke brain damage. Effective efferocytosis might be an efficient strategy to minimize inflammation and restore brain homeostasis for neuronal regeneration and function recovery. In this review, we will discuss the phagocytes in the brain, the molecular mechanisms underlying efferocytosis, the role of efferocytosis in inflammation resolution, and the potential therapeutic applications targeting efferocytosis in stroke.
